drugset / Trial / NCT04739527
Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment
NaSingle-groupOpen-labelTreatment
Summary
Phase I study to evaluate safety and systemic immunogenicity of the DCP-001 vaccine in patients with high grade serous ovarian cancer after primary treatment.
Timeline
- Start
- 2021-06-10
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCP-001 | Vaccine | 1e+07 cells | — |
| Subject | DCP-001 | Vaccine | 2.5e+07 cells | — |